Rapport Therapeutics (RAPP) Institutional Ownership $11.38 -0.17 (-1.47%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$11.36 -0.02 (-0.13%) As of 04/23/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Rapport Therapeutics (NASDAQ:RAPP)Number ofInstitutional Buyers(last 12 months)42TotalInstitutional Inflows(last 12 months)$169.14MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$2.70M Get RAPP Insider Trade Alerts Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RAPP Institutional Buying and Selling by Quarter Rapport Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/8/2025 Rhumbline Advisers14,358$144K0.0%+40.1%0.039% 4/8/2025 Catalyst Private Wealth LLC10,000$100K0.0%N/A0.027% 4/7/2025 GAMMA Investing LLC9,208$918K0.0%+91,980.0%0.025% 3/18/2025California State Teachers Retirement System8,571$152K0.0%+1,151.2%0.023% 2/17/2025Woodline Partners LP181,530$3.22M0.0%-2.7%0.496% 2/17/2025Deutsche Bank AG2,317$41K0.0%N/A0.006% 2/17/2025Crestline Management LP27,496$488K0.0%N/A0.075% 2/17/2025Bank of America Corp DE6,578$117K0.0%-65.6%0.018% 2/17/2025Acuta Capital Partners LLC16,400$291K0.3%-6.8%0.045% 2/14/2025Virtus ETF Advisers LLC3,740$66K0.0%N/A0.010% Get the Latest News and Ratings for RAPP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/14/2025T. Rowe Price Investment Management Inc.1,636,931$29.04M0.0%-5.2%4.475% 2/14/2025Price T Rowe Associates Inc. MD1,143,384$20.29M0.0%+9.2%3.126% 2/14/2025TRV GP V LLC7,135,233$126.58M43.1%N/A19.506% 2/14/2025TRV GP VI LLC969,218$17.19M14.7%N/A2.650% 2/13/2025Barclays PLC18,497$328K0.0%+43.8%0.051% 2/13/2025Legal & General Group Plc9,523$169K0.0%+947.6%0.026% 2/13/2025Wells Fargo & Company MN4,824$86K0.0%+38.9%0.013% 2/12/2025Geode Capital Management LLC210,676$3.74M0.0%+4.4%0.576% 2/12/2025Alliancebernstein L.P.1,098,415$19.49M0.0%+0.9%3.003% 2/12/2025Norges Bank48,452$860K0.0%N/A0.132% 2/12/2025JPMorgan Chase & Co.7,170$127K0.0%+77.8%0.020% 2/11/2025KLP Kapitalforvaltning AS1,900$34K0.0%N/A0.005% 2/10/2025Swiss National Bank18,000$319K0.0%N/A0.049% 1/31/2025New York State Common Retirement Fund3,500$62K0.0%N/A0.010% 1/30/2025 Rhumbline Advisers10,249$182K0.0%-35.3%0.028% 1/24/2025Jennison Associates LLC62,287$1.11M0.0%N/A0.170% 1/24/2025China Universal Asset Management Co. Ltd.7,756$138K0.0%N/A0.021% 12/26/2024JPMorgan Chase & Co.4,033$83K0.0%N/A0.011% 11/19/2024Barclays PLC12,863$264K0.0%+36.8%0.035% 11/16/2024Geode Capital Management LLC201,748$4.13M0.0%N/A0.552% 11/15/2024Barclays PLC12,863$264K0.0%+36.8%0.035% 11/15/2024State Street Corp58,046$1.19M0.0%N/A0.159% 11/15/2024Maven Securities LTD29,930$613K0.0%N/A0.082% 11/14/2024Eventide Asset Management LLC110,401$2.26M0.0%+120.8%0.302% 11/14/2024Acuta Capital Partners LLC17,600$360K0.3%-12.0%0.048% 11/14/2024MetLife Investment Management LLC5,710$117K0.0%N/A0.016% 11/13/2024BNP Paribas Financial Markets1,684$34K0.0%N/A0.005% 11/13/2024FMR LLC5,486,468$112.36M0.0%+10.1%14.999% 11/13/2024The Manufacturers Life Insurance Company77,344$1.58M0.0%+2.4%0.211% 11/12/2024Charles Schwab Investment Management Inc.73,146$1.50M0.0%N/A0.200% $2 Trillion Disappears Because of Fed's Secretive New Move (Ad)$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.Click here to see his new research now.11/7/2024LMR Partners LLP20,000$410K0.0%-60.0%0.055% 10/23/2024Values First Advisors Inc.1,507$31K0.0%N/A0.004% 10/3/2024 SG Americas Securities LLC4,934$101K0.0%N/A0.014% 8/27/2024Logos Global Management LP208,910$4.86M0.4%N/A0.591% 8/16/2024Perceptive Advisors LLC748,183$17.40M0.4%N/A2.045% 8/15/2024The Manufacturers Life Insurance Company75,516$1.76M0.0%N/A0.206% 8/15/2024Millennium Management LLC116,782$2.72M0.0%N/A0.319% 8/14/2024Squarepoint Ops LLC16,345$380K0.0%N/A0.045% 8/14/2024Sandia Investment Management LP5,000$116K0.2%N/A0.014% 8/14/2024ARCH Venture Management LLC3,728,738$86.73M31.6%N/A10.193% 8/14/2024Davidson Kempner Capital Management LP10,000$229K0.0%N/A0.027% 8/10/2024Sofinnova Investments Inc.1,951,562$45.39M2.4%N/A5.516% 8/9/2024Johnson & Johnson2,498,051$58.11M14.5%N/A7.061% 8/3/2024TD Asset Management Inc101,522$2.36M0.0%N/A0.287% (Data available from 1/1/2016 forward) RAPP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RAPP shares? During the previous two years, 47 institutional investors and hedge funds held shares of Rapport Therapeutics. The most heavily invested institutionals were TRV GP V LLC ($126.58M), FMR LLC ($112.36M), ARCH Venture Management LLC ($86.73M), Johnson & Johnson ($58.11M), Sofinnova Investments Inc. ($45.39M), T. Rowe Price Investment Management Inc. ($29.04M), and Price T Rowe Associates Inc. MD ($20.29M).Learn more on RAPP's institutional investors. Which institutional investors have been buying Rapport Therapeutics stock? Of the 42 institutional investors that purchased Rapport Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP V LLC ($7.14M), ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), TRV GP VI LLC ($969.22K), Perceptive Advisors LLC ($748.18K), and FMR LLC ($503.12K). How much institutional buying is happening at Rapport Therapeutics? Institutional investors have bought a total of 18,857,846 shares in the last 24 months. This purchase volume represents approximately $169.14M in transactions. Which Rapport Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Rapport Therapeutics stock in the last 24 months: T. Rowe Price Investment Management Inc. ($90.18K), LMR Partners LLP ($30K), Bank of America Corp DE ($12.53K), Rhumbline Advisers ($5.59K), Woodline Partners LP ($5.03K), and Acuta Capital Partners LLC ($3.60K). How much institutional selling is happening at Rapport Therapeutics? Institutional investors have sold a total of 146,936 shares in the last 24 months. This volume of shares sold represents approximately $2.70M in transactions. Related Companies VERA Institutional Ownership SPRY Institutional Ownership IRON Institutional Ownership MESO Institutional Ownership IMCR Institutional Ownership TVTX Institutional Ownership INDV Institutional Ownership EWTX Institutional Ownership OCUL Institutional Ownership CALT Institutional Ownership This page (NASDAQ:RAPP) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
